<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35507669</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1948-7193</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS chemical neuroscience</Title>
          <ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sleep-Wake Disorders in Alzheimer's Disease: A Review.</ArticleTitle>
        <Pagination>
          <StartPage>1467</StartPage>
          <EndPage>1478</EndPage>
          <MedlinePgn>1467-1478</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.2c00097</ELocationID>
        <Abstract>
          <AbstractText>Alzheimer's disease (AD) is a multifactorial disease, and it has become a serious health problem in the world. Senile plaques (SPs) and neurofibrillary tangles (NFTs) are two main pathological characters of AD. SP mainly consists of aggregated β-amyloid (Aβ), and NFT is formed by hyperphosphorylated tau protein. Sleep-wake disorders are prevalent in AD patients; however, the links and mechanisms of sleep-wake disorders on the AD pathogenesis remain to be investigated. Here, we referred to the sleep-wake disorders and reviewed some evidence to demonstrate the relationship between sleep-wake disorders and the pathogenesis of AD. On one hand, the sleep-wake disorders may lead to the increase of Aβ production and the decrease of Aβ clearance, the spreading of tau pathology, as well as oxidative stress and inflammation. On the other hand, the <i>ApoE4</i> allele, a risk gene for AD, was reported to participate in sleep-wake disorders. Furthermore, some neurotransmitters, such as acetylcholine, glutamate, serotonin, melatonin, and orexins, and their receptors were suggested to be involved in AD development and sleep-wake disorders. We discussed and suggested some possible therapeutic strategies for AD treatment based on the view of sleep regulation. In general, this review explored different views to find novel targets of diagnosis and therapy for AD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yu-Ying</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, , Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Institute of Functional Factors and Brain Science, Beijing Union University, Beijing 100023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhun</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, , Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Institute of Functional Factors and Brain Science, Beijing Union University, Beijing 100023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>He-Yan</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, , Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Institute of Functional Factors and Brain Science, Beijing Union University, Beijing 100023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Han-Chang</ForeName>
            <Initials>HC</Initials>
            <Identifier Source="ORCID">0000-0002-3574-5286</Identifier>
            <AffiliationInfo>
              <Affiliation>Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, , Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Institute of Functional Factors and Brain Science, Beijing Union University, Beijing 100023, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Chem Neurosci</MedlineTA>
        <NlmUniqueID>101525337</NlmUniqueID>
        <ISSNLinking>1948-7193</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012893" MajorTopicYN="Y">Sleep Wake Disorders</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alzheimer’s disease (AD)</Keyword>
        <Keyword MajorTopicYN="N">circadian rhythms</Keyword>
        <Keyword MajorTopicYN="N">neurotransmitters</Keyword>
        <Keyword MajorTopicYN="N">sleep−wake disorders</Keyword>
        <Keyword MajorTopicYN="N">β-amyloid (Aβ)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>14</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35507669</ArticleId>
        <ArticleId IdType="doi">10.1021/acschemneuro.2c00097</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
